• Revenue down 51.7% to $196,875 due to decreased product sales
• Net loss increased to $13.1M, up 91.6% from prior year
• Increased personnel costs to support European sales and product launches

Imricor Medical Systems, Inc. reported its financial results for the six months ended June 30, 2025. Total revenue for the period was $196,875, down 51.7% from $407,756 in the prior corresponding period, primarily due to a decrease in product sales. Total product sales of $155,797 were down 53% compared to the prior year. The net loss for the period increased to $13,141,353, up 91.6% from $6,858,199 in the prior year, driven by changes in the fair value of convertible notes and derivative liabilities, partially offset by a foreign currency exchange gain. Excluding these items, the adjusted net loss was 26% higher than the prior year, due to increases in personnel costs as the company grew its sales and marketing team to support its European expansion and upcoming product launches, as well as timing of costs related to clinical trials and regulatory submissions. The company obtained CE Mark approval for its second-generation products and continues to work towards FDA approval in the US.